Navigation Links
Anaptys Biosciences Raises Over $33 Million in Series B Financing
Date:11/8/2007

New Capital to Support Continued Advancement of Novel Technology and

Product Portfolio

LA JOLLA, Calif., Nov. 8 /PRNewswire/ -- Anaptys Biosciences, Inc., a privately-held therapeutic antibody product company, today announced that it has raised $33.9 million in a Series B equity financing led by Novo A/S. Additional investors participating significantly in the round were Frazier Healthcare Ventures and Alloy Ventures, along with founding investor Avalon Ventures. Completing the syndicate were Numenor Ventures, WS Investment Company, and Anaptys board member, Dr. Nick Lydon.

The new investment capital will support continued advancement of the company's novel technology for therapeutic antibody discovery and optimization, and building a pipeline of product candidates.

"We are pleased to have attracted such a strong investor group to support the company's multiple development programs," said Tom Smart, chairman and chief executive officer of Anaptys. "In addition to providing significant financial resources, these experienced investors bring Anaptys a wealth of operational, medical, and industry expertise along with key relationships that will serve the company well during this important stage of growth and achievement."

In connection with the financing, Heath Lukatch, Ph.D., of Novo A/S, James N. Topper, M.D., Ph.D., of Frazier Healthcare Ventures, and J. Leighton Read, M.D., of Alloy Ventures will join the Anaptys Board of Directors together with existing members Kevin J Kinsella of Avalon Ventures, Nick Lydon, Ph.D., of Granite Biopharma, LLC, R. Scott Greer of Numenor Ventures, and Anaptys executives William Boyle, Ph.D., and Tom Smart.

"It is a great pleasure for Novo A/S to lead this investment in Anaptys," said Dr. Lukatch. "The company has developed powerful technologies to quickly and cost effectively optimize antibodies against a variety of high value targets. By harnessing the efficiency of somatic hypermutation for antibody evolution and optimization, Anaptys' innovative Omnitope-SHM(TM) System has the potential to usher in a new generation of best-in-class therapeutic antibodies."

About Anaptys Biosciences, Inc.

Anaptys is a privately-held developer of therapeutic antibody products and the leader in the use of SHM for antibody discovery and optimization. SHM, or somatic hypermutation, is the body's natural process for generating antibody diversity to fight disease. The company's Omnitope-SHM(TM) System utilizes the key components of SHM to enable the rapid generation and selection of antibodies for therapeutic applications. The versatile platform can be applied to the de novo discovery and optimization of antibodies directed to a chosen disease target, as well as affinity mature an existing antibody to improve its binding potency. Anaptys is using the platform to build a pipeline of product candidates with significant medical and commercial potential. For more information, visit the company's web site at http://www.anaptysbio.com.

About Novo A/S

Novo A/S is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. Novo Ventures is recognized as a significant force within life science venture capital and is active in both Europe and North America. The Novo Ventures team consists of six Partners in Copenhagen, one in London, and two in San Francisco.

With an evergreen structure, Novo A/S annually invests approximately $90 million in venture capital into private life sciences companies and acts at a pace comparable to a traditional $400 million fund. Novo A/S is not a corporate strategic fund; the group invests for financial rather than strategic returns. In total, Novo A/S has more than $10 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S. For more information, visit http://www.novo.dk.


'/>"/>
SOURCE Anaptys Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. BlueCare(R) Family Plan, a HUSKY Health Plan from Anthem Blue Cross and Blue Shield in Connecticut, Raises Awareness, Funds and Diapers for New Haven Diaper Bank
8. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
9. Fifth Annual Avon Walk for Breast Cancer Los Angeles Raises $4.3 Million
10. AHIP Praises Bipartisan Senate Vote on Mental Health Parity
11. Union President Praises Hillary Clintons Health Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... 2016 Research and Markets ... Electronics 2015-2025: Applications, Technologies, Forecasts" report to ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, Composite ... Structural electronics involves electronic and/or electrical components and ... dumb structures such as vehicle bodies or conformally ...
Breaking Medicine Technology: